BIP - Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
The primary objective of this study is to assess the efficacy of Ocrelizumab (OCR) in Relapsing Multiple Sclerosis patients who have been previously treated with natalizumab (NTZ) by evaluating relapse rate, progression on MRI and disability progression.
-Must have received 12 or more consecutive monthly infusions of natalizumab (Tysabri).
-Naïve to ocrelizumab (Ocrevus).
Key Exclusion Criteria:
-Patients with a known history of hepatitis B, hepatitis C, tuberculosis, PML, or who are HIV positive.
-Previous treatment with B-cell targeted therapies.
-Patients who have had evidence of disease activity within the 6 months prior to screening. This includes MS relapse, or new or enlarging T2 lesions or Gd+ enhancing lesions, or disability progression.
**Other protocol-defined inclusion/exclusion criteria may apply. Please click on the NCT Number (below) to learn more about the study at clinicaltrials.gov.**
Kyle E Smoot, M.D.
Providence Health & Services
- Providence St. Vincent Medical Center
- St. Barnabas Medical Center
- Swedish Medical Center